Indirect evidence for proton pump inhibitor failure in patients taking them independent of meals

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 7, 2014, Pages 768-772

  Freigofas, Julia ^a   Haefeli, Walter E ^a   Schöttker, Ben ^b   Brenner, Hermann ^b   Quinzler, Renate ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Food intake; Pharmacoepidemiology; Proton pump inhibitor; Treatment failure

Indexed keywords

ANTACID AGENT; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ARTICLE; COHORT ANALYSIS; DRUG TREATMENT FAILURE; ELDERLY CARE; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MEAL; PATIENT CARE; PATIENT COUNSELING; PEPTIC ULCER; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; AGED; FEMALE; FOLLOW UP; FOOD DRUG INTERACTION; MALE; MIDDLE AGED; PATIENT EDUCATION; PROCEDURES; TREATMENT FAILURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PROTON PUMP INHIBITORS; TREATMENT FAILURE;

EID: 84903820212     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3620     Document Type: Article

References (15)

1. IMSHealth. TOP 25 Medicines by Dispensed Prescriptions (U.S.) 2012. http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/Press%20Room/2012_U.S/Top_25_Medicines_Dispensed_Prescriptions_U.S..pdf.
2. Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008; 10: 252-257.
3. Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44: 441-466.
4. Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch 2009; 457: 609-622. doi:10.1007/s00424-008-0495-4.
5. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267-1272.
6. Dickman R, Boaz M, Aizic S, Beniashvili Z, Fass R, Niv Y. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011; 17: 387-394. doi:10.5056/jnm.2011.17.4.387.
7. Low M, Stegmaier C, Ziegler H, Rothenbacher D, Brenner H, ESTHER study. Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study). Dtsch Med Wochenschr 2004; 129: 2643-2647. doi:10.1055/s-2004-836089.
8. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27-31.
9. Cross LB, Justice LN. Combination drug therapy for gastroesophageal reflux disease. Ann Pharmacother 2002; 36: 912-916.
10. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease
11. Gunaratnam NT, Jessup TP, Inadomi J, Lascewski DP. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473-1477. doi:10.1111/j.1365-2036.2006.02911.x.
12. Hungin AP, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999; 49: 463-464.
13. Thomson AB, Sinclair P, Matisko A, Rosen E, Andersson T, Olofsson B. Influence of food on the bioavailability of an enteric-coated tablet formulation of omeprazole 20mg under repeated dose conditions. Can J Gastroenterol 1997; 11: 663-667.
14. Katz PO, Castell DO, Chen Y, Andersson T, Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004; 20: 399-406. doi:10.1111/j.1365-2036.2004.02079.x.
15. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-167.